Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Essential Hypertension Clear all
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

NCT07109739
View directory record Official record
Conditions
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Interventions
POWERbreathe K5
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Not applicable Interventional

The Northwest Coalition for Primary Care Practice Support

NCT02839382
View directory record Official record
Conditions
Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
Interventions
Coaching, Educational Outreach, Site Visits
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

NCT04505618
View directory record Official record
Conditions
Diabetic Retinopathy, Retinal Vein Occlusion, Hypertension,Essential, Retinal Vascular Disorder
Interventions
Swept-Source (SS) OCT Angiography, Spectral-Domain (SD) OCT Angiography, Fundus Imaging, Axial Length Measurement Device
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting Not applicable Interventional

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638
View directory record Official record
Conditions
Hypertension, Hypertension, Systolic, Hypertension, Essential
Interventions
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
72
States / cities
Scottsdale, Arizona • Glendale, California • Newport Beach, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

NCT00662896
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg bid, naproxcinod 750 mg bid, naproxen 250 mg bid, naproxen 500 mg bid, ibuprofen 600 mg tid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
57
States / cities
Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Not applicable Interventional

Skills-Based Educational Strategies for Reduction of Vascular Events in Orange County

NCT05641519
View directory record Official record
Conditions
Hypertension
Interventions
SERVE OC Intervention, Enhanced Standard Intervention
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
5 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Recruiting No phase listed Observational

Childhood-Onset Essential Hypertension Natural History Study

NCT06778239
View directory record Official record
Conditions
Hypertension, Essential Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086
View directory record Official record
Conditions
Hypertension
Interventions
LFF269, Eplerenone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 20, 2026, 5:43 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of Gene Variants on Dopamine Receptor Natriuretic Responses

NCT00592150
View directory record Official record
Conditions
Hypertension
Interventions
fenoldopam, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01150357
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 20, 2026, 5:43 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

NCT03179163
View directory record Official record
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

NCT00294710
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Not yet recruiting Not applicable Interventional

Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension

NCT07679984
View directory record Official record
Conditions
Hypertension, Essential (Primary) Hypertension
Interventions
Mindfulness in Motion
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

NCT00662610
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

NCT00219024
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure

NCT00537043
View directory record Official record
Conditions
Hypertension
Interventions
SK&F-105517 (COREG CR FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

NCT00779181
View directory record Official record
Conditions
Hypertension
Interventions
ADX415, Placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 20, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 20, 2026, 5:43 AM EDT